Novartis pays $1B upfront for PTC’s Phase 2 Huntington’s drug - Endpoints News
Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for access to a Phase 2 oral drug.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 54b2e80, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments